Related Experiment Video
Updated: Mar 31, 2026
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells
Published on: May 6, 2013
P2X7 receptor knockout prevents streptozotocin-induced type 1 diabetes in mice
Flávia Sarmento Vieira1, Hayandra Ferreira Nanini1, Christina Maeda Takiya2
1Laboratório de Imunofisiologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Abstract:
Type 1 diabetes (T1D) is caused by autoimmune destruction of islet of Langerhans β-cells. P2X7 receptors (P2X7R) modulate proinflammatory immune responses by binding extracellular ATP, a classic 'danger signal'. Here, we evaluated whether the P2X7R has a role in T1D development. P2X7(-/-) mice are resistant to TD1 induction by streptozotocin (STZ) treatment, with no increase in blood glucose, decrease in insulin-positive cells, and pancreatic islet reduction, compared to WT (C57BL/6) mice. Also, the levels of proinflammatory mediators (IL-1β, IFN-γ and NO) did not increase after STZ treatment in P2X7(-/-) animals, with reduced infiltration of CD4(+), CD8(+), B220(+), CD11b(+) and CD11c(+) cells in the pancreatic lymph nodes. Treatment with a P2X7 antagonist mimicked the effect of P2X7 knockout, preventing STZ-induced diabetes. Our results show that the absence of the P2X7R provides resistance in the induction of diabetes in this model, and suggest that therapy targeting the P2X7R may be useful against clinical T1D.
Insights
Mice lacking P2X7 receptors (P2X7R) resisted type 1 diabetes (T1D) induction. Targeting P2X7R may offer a new therapy for clinical T1D by reducing inflammation and immune cell infiltration.
Area of Science:
- Immunology
- Endocrinology
- Pharmacology
Background:
- Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells.
- P2X7 receptors (P2X7R) are involved in inflammatory responses, triggered by extracellular ATP.
- The role of P2X7R in T1D pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the role of P2X7R in the development of type 1 diabetes.
- To evaluate the therapeutic potential of P2X7R antagonism in a mouse model of T1D.
Main Methods:
- Utilized P2X7 receptor knockout (P2X7(-/-)) and wild-type (WT) mice.
- Induced diabetes using streptozotocin (STZ) in P2X7(-/-) and WT mice.
- Administered a P2X7 receptor antagonist to WT mice.
- Assessed blood glucose, insulin levels, pancreatic islet morphology, inflammatory mediators, and immune cell infiltration.
Main Results:
- P2X7(-/-) mice were resistant to STZ-induced diabetes, showing no hyperglycemia, preserved insulin-positive cells, and intact islets.
- STZ treatment did not elevate proinflammatory mediators (IL-1β, IFN-γ, NO) in P2X7(-/-) mice.
- Reduced infiltration of immune cells (CD4+, CD8+, B220+, CD11b+, CD11c+) was observed in pancreatic lymph nodes of P2X7(-/-) mice.
- P2X7 receptor antagonist treatment protected WT mice from STZ-induced diabetes.
Conclusions:
- Absence of P2X7R confers resistance to T1D induction in the STZ model.
- P2X7R plays a critical role in mediating the inflammatory processes underlying T1D development.
- Targeting P2X7R represents a potential therapeutic strategy for clinical T1D.
